Heather Lanigan, U.S. Trade and Development Agency
Lawrence Evans III, USP
Noemia Muíssa Escrivao, Medicines Regulatory Authority (ANARME)
Ikechukwu Sylvester Ofuani, Johnson & Johnson
Resource constraints and the complexity of regulatory systems has been well documented. This has also impacted the level of investment from private sector companies in the African healthcare sector. The COVID-19 pandemic underscored the need for robust regulatory systems that are responsive to public health needs. Post the pandemic, with the focus on the African Continental Free Trade Agreement (AfCFTA) and the operationalization of the African Medicines Agency, investment in the pharmaceutical and vaccines sector has been prioritized. In parallel, international partners have been focused on capacity building initiatives with several regulatory agencies across the continent.
As Africa continues to make progress, it’s now critical to translate these initiatives into an investor friendly climate for new and existing players in the sector. Early access to markets through efficient regulatory systems, ease of distribution and logistics, and transparent and well- governed procurement mechanisms will be critical for further sector development and improving public health. This panel will convene public and private sector leaders to explore opportunities to create an enabling environment for investment through efficient, transparent, adaptable and predictable regulatory mechanisms that leverage private sector capabilities through partnership and collaboration.
650 S Griffin St.
Dallas, TX 75202
United States